Reply: Beyond the limits of detection: failure of PiB imaging to capture true Aβ burden.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research.Molecules (Basel, Switzerland) · 2022
   Review
2. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2015
   Article

Corrections and comments

• Comment on
  Brain amyloid and cognition in Lewy body diseases.2012
• Comment on
  Beyond the limits of detection: failure of PiB imaging to capture true Aβ burden.2013

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as